![]() Patients should be advised to tell their anaesthetist if they think they have previously taken pholcodine. Where appropriate, healthcare professionals should also check whether patients who are scheduled to undergo general anaesthesia with NMBAs have used pholcodine, particularly in the previous 12 months and remain vigilant for the risk of anaphylaxis in these patients. Pharmacists should consider recommending appropriate treatment alternatives for patients who present with a new dry cough or who are currently taking pholcodine. Healthcare professionals should recommend appropriate treatment alternatives when counselling patients who may present with symptoms of cough, cold and flu. This recall applies to all batches currently within shelf-life for the products listed. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process. Stop supplying the above products immediately. Please see link to Drug Safety Update (DSU) for further information. All pholcodine-containing medicines are Pharmacy (P) only medicines and therefore have only been sold or dispensed under the supervision of a suitably trained healthcare professional. Given the advice of the CHM, and the lack of identifiable effective measures to minimise the increased risk of anaphylactic reactions to NMBAs, pholcodine-containing medicines are being withdrawn from the UK market and will therefore no longer be available in pharmacies. The available data has demonstrated that pholcodine use, particularly in the 12 months before general anaesthesia with NMBAs, is a risk factor for developing an anaphylactic reaction to NMBAs. The Commission on Human Medicines (CHM), the independent advisory body that provides expert advice on the safety, quality and efficacy of medicines, has considered the evidence of an increased risk of the very rare event of anaphylaxis when exposed to neuromuscular blocking agents (NMBA) and advised that pholcodine-containing medicines should be withdrawn. Day & Night Nurse Capsules, PL 44673/0068įollowing the conclusion of a review of post-marketing safety data by the MHRA, all pholcodine-containing medicines are being recalled and withdrawn from the UK as a precaution.Pholcodine Linctus, PL 12965/0030 Glaxosmithkline Consumer Healthcare (UK) Trading Limited Strong Pholcodine Linctus BP, PL 04917/0005.Strong Pholcodine Linctus BP, PL 03105/0060.Superdrug Pholcodine Linctus BP, PL 03105/0059.Well Pharmaceuticals Pholcodine 5mg per 5ml Oral Solution, PL 03105/0059.Numark Pholcodine 5mg per 5ml Oral Solution, PL 03105/0059.Pholcodine Linctus Bells Healthcare 5mg Per 5ml Oral Solution, PL 03105/0059.Covonia Dry Cough Sugar Free Formula, PL 00240/0353.Galenphol Strong Linctus, PL 00240/0103.Galenphol Paediatric Linctus, PL 00240/0102.Care Pholcodine 5mg/5ml Oral Solution Sugar Free, PL 00240/0101.Boots Day Cold & Flu Relief Oral Solution, PL 00014/0565. ![]() Boots Dry Cough Syrup 6 Years+, PL 00014/0523.Boots Night Cough Relief Oral Solution, PL 00014/0230.MDR 008-12/22 Company name The Boots Company PLC
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |